← Leaderboards
Richard A. Van Etten
Immune Disease Institute, Inc.
$23,623,241
Attributed
$25,698,092
Total exposure
17
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$51,197,275 · 18
By mechanism
P30$31,984,046 · 7
R01$15,733,337 · 8
U54$1,795,417 · 1
T32$1,178,926 · 1
P01$505,549 · 1
Top collaborators
- Katia Georgopoulos5 shared
- Hans Klingemann2 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMolecularPathogenesisClinical ResearchLeukemiaFundingProgramsMouse ModelCancer CenterIn VivoBiologyCancer Center Support GrantComprehensive Cancer CenterFutureClinical TrialsLeadershipInhibitor/AntagonistPhiladelphia ChromosomeMutationDisease RemissionResource SharingPathway InteractionsCellsCollaborations
Grant awards (97)
Cancer Center Support Grant$2,352,380
P30 · FY2025 · CA · contact PI
Understanding critical transitions in chronic myeloid leukemia to improve tyrosine kinase inhibitor therapy$505,549
P01 · FY2025 · CA · contact PI
Mechanisms of treatment-free remission in a mouse model of chronic myeloid leukemia$359,138
R01 · FY2025 · CA · contact PI
Administration$191,211
P30 · FY2025 · CA · contact PI
Clinical Trial Advancement and Development for Sarcomas$70,000
P30 · FY2025 · CA · contact PI
Cancer Center Support Grant$2,349,767
P30 · FY2024 · CA · contact PI
Mechanisms of treatment-free remission in a mouse model of chronic myeloid leukemia$359,138
R01 · FY2024 · CA · contact PI
Administration$186,786
P30 · FY2024 · CA · contact PI
Cancer Center Support Grant$2,342,788
P30 · FY2023 · CA · contact PI
Leadership, Planning and Evaluation$320,415
P30 · FY2023 · CA · contact PI
Developmental Funds$190,906
P30 · FY2023 · CA · contact PI
Cancer Center Support Grant$2,331,260
P30 · FY2022 · CA · contact PI
Project 3: Modeling Malignant Myelopoiesis to Increase Efficacy of Targeted Leukemia Therapy$350,367
U54 · FY2022 · CA · contact PI
Leadership, Planning and Evaluation$317,759
P30 · FY2022 · CA · contact PI
Developmental Funds$209,681
P30 · FY2022 · CA · contact PI
Project 3: Modeling Malignant Myelopoiesis to Increase Efficacy of Targeted Leukemia Therapy$395,609
U54 · FY2021 · CA · contact PI
STUDIES OF BCR-ABL LEUKEMOGENESIS IN MICE$293,550
R01 · FY2021 · CA · contact PI
Cancer Center Support Grant$2,317,500
P30 · FY2020 · CA · contact PI
Cancer Center Support Grant$785,000
P30 · FY2020 · CA · contact PI
Developmental Funds$669,665
P30 · FY2020 · CA · contact PI
Project 3: Modeling Malignant Myelopoiesis to Increase Efficacy of Targeted Leukemia Therapy$363,112
U54 · FY2020 · CA · contact PI
Administration$346,198
P30 · FY2020 · CA · contact PI
STUDIES OF BCR-ABL LEUKEMOGENESIS IN MICE$293,550
R01 · FY2020 · CA · contact PI
Planning and Evaluation$84,706
P30 · FY2020 · CA · contact PI
Cancer Center Support Grant$2,317,493
P30 · FY2019 · CA · contact PI
Developmental Funds$669,695
P30 · FY2019 · CA · contact PI
Role of IKAROS in the Biology and Therapy of High-Risk Precursor B-Cell Leukemia$527,781
R01 · FY2019 · CA · contact PI
Project 3: Modeling Malignant Myelopoiesis to Increase Efficacy of Targeted Leukemia Therapy$355,170
U54 · FY2019 · CA · contact PI
Administration$346,201
P30 · FY2019 · CA · contact PI
STUDIES OF BCR-ABL LEUKEMOGENESIS IN MICE$284,743
R01 · FY2019 · CA · contact PI
Planning and Evaluation$84,710
P30 · FY2019 · CA · contact PI
Cancer Center Support Grant$2,317,496
P30 · FY2018 · CA · contact PI
Developmental Funds$669,725
P30 · FY2018 · CA · contact PI
Role of IKAROS in the Biology and Therapy of High-Risk Precursor B-Cell Leukemia$544,106
R01 · FY2018 · CA · contact PI
Administration$346,204
P30 · FY2018 · CA · contact PI
Project 3: Modeling Malignant Myelopoiesis to Increase Efficacy of Targeted Leukemia Therapy$331,159
U54 · FY2018 · CA · contact PI
STUDIES OF BCR-ABL LEUKEMOGENESIS IN MICE$293,550
R01 · FY2018 · CA · contact PI
Planning and Evaluation$84,711
P30 · FY2018 · CA · contact PI
Cancer Center Support Grant$2,317,496
P30 · FY2017 · CA · contact PI
Role of IKAROS in the Biology and Therapy of High-Risk Precursor B-Cell Leukemia$544,106
R01 · FY2017 · CA · contact PI
Developmental Funds$384,709
P30 · FY2017 · CA · contact PI
STUDIES OF BCR-ABL LEUKEMOGENESIS IN MICE$293,550
R01 · FY2017 · CA · contact PI
Administration$198,868
P30 · FY2017 · CA · contact PI
Planning and Evaluation$48,661
P30 · FY2017 · CA · contact PI
Cancer Center Support Grant$2,282,863
P30 · FY2016 · CA · contact PI
Developmental Funds$596,209
P30 · FY2016 · CA · contact PI
Role of IKAROS in the Biology and Therapy of High-Risk Precursor B-Cell Leukemia$544,106
R01 · FY2016 · CA · contact PI
Administration$462,432
P30 · FY2016 · CA · contact PI
Studies of BCR-ABL leukemogenesis in mice$274,559
R01 · FY2016 · CA · contact PI
Planning and Evaluation$75,411
P30 · FY2016 · CA · contact PI
University of California, Irvine Cancer Center Support Grant$1,213,480
P30 · FY2015 · CA · contact PI
Role of IKAROS in the Biology and Therapy of High-Risk Precursor B-Cell Leukemia$557,731
R01 · FY2015 · CA · contact PI
Studies of BCR-ABL leukemogenesis in mice$274,559
R01 · FY2015 · CA · contact PI
University of California, Irvine Cancer Center Support Grant$48,256
P30 · FY2015 · CA · contact PI
University of California, Irvine Cancer Center Support Grant$1,211,843
P30 · FY2014 · CA · contact PI
Studies of BCR-ABL leukemogenesis in mice$266,107
R01 · FY2014 · CA · contact PI
University of California, Irvine Cancer Center Support Grant$73,445
P30 · FY2014 · CA · contact PI
University of California, Irvine Cancer Center Support Grant$1,168,116
P30 · FY2013 · CA · contact PI
Studies of BCR-ABL leukemogenesis in mice$112,079
R01 · FY2013 · CA · contact PI
Molecular Pathogenesis & Therapy of JAK2 V617F-induced Myeloproliferative Disease$398,475
R01 · FY2012 · HL · contact PI
Studies of BCR-ABL leukemogenesis in mice$304,498
R01 · FY2012 · CA · contact PI
Research Training in Oncology$224,218
T32 · FY2012 · CA · contact PI
Research Training in Oncology$72,572
T32 · FY2012 · CA · contact PI
Molecular Pathogenesis & Therapy of JAK2 V617F-induced Myeloproliferative Disease$402,500
R01 · FY2011 · HL · contact PI
Research Training in Oncology$264,130
T32 · FY2011 · CA · contact PI
Research Training in Oncology$71,419
T32 · FY2011 · CA · contact PI
Novel Cellular Therapies for Ph+ leukemia$724,784
R01 · FY2010 · HL · contact PI
Molecular Pathogenesis & Therapy of JAK2 V617F-induced Myeloproliferative Disease$402,500
R01 · FY2010 · HL · contact PI
Studies of BCR/ABL Leukemogenesis in Mice$286,110
R01 · FY2010 · CA · contact PI
Research Training in Oncology$237,148
T32 · FY2010 · CA · contact PI
Research Training in Oncology$70,291
T32 · FY2010 · CA · contact PI
Novel Cellular Therapies for Ph+ leukemia$707,089
R01 · FY2009 · HL · contact PI
Molecular Pathogenesis & Therapy of JAK2 V617F-induced Myeloproliferative Disease$402,500
R01 · FY2009 · HL · contact PI
Studies of BCR/ABL Leukemogenesis in Mice$286,110
R01 · FY2009 · CA · contact PI
Research Training in Oncology$239,148
T32 · FY2009 · CA · contact PI
Molecular Pathogenesis & Therapy of JAK2 V617F-induced Myeloproliferative Disease$402,500
R01 · FY2008 · HL · contact PI
Pathogenesis & Therapy of 8p11 Leukemia/Lymphoma$316,836
R01 · FY2008 · CA · contact PI
Studies of BCR/ABL Leukemogenesis in Mice$286,110
R01 · FY2008 · CA · contact PI
Pathogenesis & Therapy of 8p11 Leukemia/Lymphoma$316,836
R01 · FY2007 · CA · contact PI
Studies of BCR/ABL Leukemogenesis in Mice$286,110
R01 · FY2007 · CA · contact PI
Pathogenesis & Therapy of 8p11 Leukemia/Lymphoma$326,298
R01 · FY2006 · CA · contact PI
Studies of BCR/ABL Leukemogenesis in Mice$295,569
R01 · FY2006 · CA · contact PI
STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE$338,674
R01 · FY2005 · CA
Pathogenesis &Therapy of 8p11 Leukemia/Lymphoma$334,150
R01 · FY2005 · CA
Pathogenesis &Therapy of 8p11 Leukemia/Lymphoma$333,125
R01 · FY2004 · CA
STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE$296,186
R01 · FY2004 · CA
STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE$248,074
R01 · FY2003 · CA
STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE$145,040
R01 · FY2003 · CA
STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE$391,956
R01 · FY2002 · CA
INHIBITOR OF THE C ABL TYROSINE KINASE$173,095
R01 · FY2002 · CA
INHIBITOR OF THE C ABL TYROSINE KINASE$119,088
R01 · FY2002 · CA
STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE$353,331
R01 · FY2001 · CA
INHIBITOR OF THE C ABL TYROSINE KINASE$283,674
R01 · FY2001 · CA
REGULATION AND FUNCTION OF C AB1 NUCLEAR TYROSINE KINASE$231,818
R01 · FY2001 · CA
STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE$18,750
R01 · FY2001 · CA
INHIBITOR OF THE C ABL TYROSINE KINASE$275,408
R01 · FY2000 · CA
REGULATION AND FUNCTION OF C AB1 NUCLEAR TYROSINE KINASE$223,790
R01 · FY2000 · CA